Post by
Pimpovish on Jan 18, 2021 9:36pm
$29 million vs $525 million
HEM closed today with a marketcap of $29 million.
SVA closed at a marketcap of $525 million. Wtf.
HEM has 91 patents, 10 years of data around an enrolment of 500 patients and is in Phase 2 (Orphan Drug Status) of an FDA clinical for Critical Limb Ischemia. They are waiting for midpoint results that could accelerate them to a Phase 3.
SVA is in Phase 1/2 of a clinical trial to test the efficacy of a Patented Cell Pouch that doses purified islets (portions of tissue) at intervals for diabetics. ONLY 5 PATIENTS were enrolled in the study!
This disconnect is completely irrational. It now behooves management of the company to more broadly communicate their messaging. Aside from InvestorIntel for IR, I don't see or hear about this company from any other media outlet. I maintain the only reason investors are buying in at this gift pricing is solely because of a lack of promotion. Ed Vranic wrote a nice short piece on HEM. He is a shrewd investor who looks for special situations like this. Granted, the company has only recently emerged from a legal cloud however the current marketcap is hard to rationalize. Long holders and new investors that found their way here are due for a potentially massive wealth creating opportunity. Time willl tell....
Comment by
Dudeforever on Jan 18, 2021 9:44pm
In case anyone is interested, a $525 million market cap would bring us to a share price of $9.41. These predictions of $5-7 are not far-fetched.